Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01758588 · ClinicalTrials.gov registry record · Phase 2
Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01758588 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 8 participants.
The verdict
NCT01758588, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the effectiveness of giving patients who have been newly diagnosed with untreated early stage primary myelofibrosis (PMF) a study drug called PEGINTRON (also known as pegylated interferon alfa 2b). This intervention will be compared to the widely employed "watch and wait" (best supportive care) approach for early stage PMF, in which patients are followed closely and treatment initiated only if the disease progresses.
Interventions
- DRUG Peginterferon alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-01 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01758588
The ClinicalTrials.gov registry entry for NCT01758588 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peginterferon alfa-2a is the first listed.
NCT01758588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01758588 about?
NCT01758588 is a clinical study titled "Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis". The purpose of this study is to look at the effectiveness of giving patients who have been newly diagnosed with untreated early stage primary myelofibrosis (PMF) a study drug called PEGINTRON (also known as pegylated interferon alfa 2b). This intervention will be compared to the widely employed "wat...
What is the current status of trial NCT01758588?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-01. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01758588?
The interventions under investigation include: Peginterferon alfa-2a (DRUG).
Who is sponsoring clinical trial NCT01758588?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.